UBS Upgrades Cepheid Stock, But Lowers Price Target | GenomeWeb
NEW YORK (GenomeWeb News) – Investment bank UBS yesterday upgraded Cepheid’s shares from “Neutral” to “Buy” based on the current valuation of the stock.
 
Analyst Derik De Bruin noted in a research note that Cepheid’s stock is down 40 percent from its peak of $32.83 in late January and February, “due in part to insider selling, conflicting views on the importance of universal MRSA testing in the medical literature, and reimbursement confusion.” He wrote that the stock’s current valuation is “compelling.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.